Supplementary Material for:

Orthogonal Optical Control of a G Protein-Coupled Receptor with a SNAP-Tethered Photochromic Ligand

Johannes Broichhagen,†‡§ Arunas Damijonaitis,†‡§ Joshua Levitz,§∥ Kevin R. Sokol,†‡ Philipp Leippe,†‡ David Konrad,†‡ Ehud Y. Isacoff,∥⊥,∥ and Dirk Trauner*,†‡

†Department of Chemistry, Ludwig-Maximilians-Universitaet Muenchen, Butenandtstrasse 5-13, 81377 Muenchen, Germany
‡Munich Center for Integrated Protein Science, Butenandtstrasse 5-13, 81377 Muenchen, Germany
∥Department of Molecular and Cell Biology, University of California, Berkeley, California 94720, United States
⊥Helen Wills Neuroscience Institute, University of California, Berkeley, California 94720, United States
#Physical Bioscience Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, United States

Corresponding Author
*E-mail: Dirk.Trauner@lmu.de.

Author Contributions §J.B., A.D., and J.L.: equal contribution.
Contents

1  Experimental ........................................................................................................................................... 5
  1.1  General ................................................................................................................................................. 5
  1.2  Synthesis of BGAGs ................................................................................................................................. 6
    1.2.1  N-(4-(((2-Amino-9H-purin-6-yl)oxy)methyl)benzyl)pent-4-ynamide (3) ........................................ 7
    1.2.2  N-(4-(((2-Amino-9H-purin-6-yl)oxy)methyl)benzyl)-4-(11,12-dehydrodibenzo[b,f]azocin-5(6H)-yl)-4-oxobutanamide (5) ................................................................. 8
    1.2.3  (2S,4S)-2-((E)-4-((2-Aminoacetamido)phenyl)diazenyl)phenyl)amino)-4-oxobutyl)-4-((tert-butoxycarbonyl)amino)pentanedioic acid (6) ........................................... 9
    1.2.4  (2S,4S)-2-(4-(((E)-4-((2-azidopropanamido)acetamido)phenyl)diazenyl)phenyl)-amino)-4-oxobutyl)-4-((tert-butoxycarbonyl)amino)pentanedioic acid (14) .......... 10
    1.2.5  (2S,4S)-2-((E)-4-((2-3-(4-((2-amino-9H-purin-6-yl)oxy)methyl)benzyl)amino)-3-oxopropyl)-1H,1,2,3-triazol-1-yl)propanamido)acetamido)-phenyl)diazenyl)phenyl)amino)-4-oxobutyl)pentanedioic acid, BGAG9 .......................... 11
    1.2.6  (2S,4S)-2-(4-(((E)-4-(((1-Azido-15-oxo-3,6,9,12-tetraoxa-16-azaoctadecan-18-yl)amino)phenyl)diazulenyl)phenyl)amino)-4-oxobutyl)-4-((tert-butoxycarbonyl)-amino)pentanedioic acid (15) .................................................. 12
    1.2.7  (2S,4S)-2-Amino-4-((E)-4-((1-4-((2-amino-9H-purin-6-yl)oxy)methyl)benzyl)amino)-3-oxopropyl)-1H,1,2,3-triazol-1-yl)-15-oxo-3,6,9,12-tetraoxa-16-aza-octadecan-18-amido)phenyl)diazenyl)phenyl)amino)-4-oxobutyl)-pentanedioic acid, BGAG4 ........................................... 13
    1.2.8  (2S,4S)-2-((E)-4-(((1-Azido-27-oxo-3,6,9,12,15,18,21,24-octa-oxa-28-azatriacontan-30-yl)amino)phenyl)diazulenyl)phenyl)amino)-4-oxobutyl)-4-((tert-butoxycarbonyl)-amino)pentanedioic acid (16) ................................................................. 14
    1.2.9  (2S,4S)-2-Amino-4-((E)-4-((1-4-((2-amino-9H-purin-6-yl)oxy)methyl)benzyl)amino)-3-oxopropyl)-1H,1,2,3-triazol-1-yl)-27-oxo-3,6,9,12,15,18,21,24-octa-oxa-28-azatriacontan-30-amido)phenyl)diazenyl)phenyl)amino)-4-oxobutyl)pentane-dioic acid, BGAG8 ......................................................................................... 15
    1.2.10 (2S,4S)-2-((E)-4-((1-Azido-39-oxo-3,6,9,12,15,18,21,24,27,30,33,36-dodecaoxa-40-azadotetracontan-42-amido)phenyl)diazulenyl)phenyl)amino)-4-oxobutyl)-4-((tert-butoxycarbonyl)amino)pentanedioic acid (17) ........................................................................................................... 16
    1.2.11 (2S,4S)-2-Amino-4-((E)-4-((1-4-((2-amino-9H-purin-6-yl)oxy)methyl)benzyl)amino)-3-oxopropyl)-1H,1,2,3-triazol-1-yl)-39-oxo-3,6,9,12,15,18,21,24,27,30,33,36-dodecaoxa-40-azadotetracontan-42-amido)phenyl)diazulenyl)phenyl)amino)-4-oxobutyl)pentanedioic acid, BGAG12 .................................................................................................................. 17
    1.2.12 (2S,4S)-2-((E)-4-((2-aminoethyl)amino)-4-oxobutyl)-4-((tert-butoxycarbonyl)amino)pentanedioic acid (10) ............................................................................................................. 18
1.2.13 (2S,4S)-2-[(4-[(4-((1-azido-39-o xo-3,6,9,12,15,18,21,24,27,30,33,36-dodecaox a-40-azadotetracontan-42-yl)amino)phenyl]diazenyl)phenyl]amino)-4-oxobutyl]-4-((ter t-butoxycarbonyl)amino)pentanedioic acid, (18) ........................................................................................................... 20
1.2.14 (2S,4S)-2-amino-4-[(4-((1-8-(4-((2-amino-9H-purin-6-yl)oxy)methyl)benzy l)amino)-4-oxobutanolyl)-8,9-dihydro-1H-dibenz[b,f][1,2,3]triazolo[4,5-d]azocin-1-yl)-39-oxo-3,6,9,12,15,18,21,24,27,30,33,36-dodecaoxa-40-azadotetracontan-42-yl)amino)phenyl]diazenyl)phenyl]amino)-4-oxobutyl]pentanedioic acid, BGAG_{12,460} .............................................................................. 21
1.2.15 (2S,4S)-2-Amino-4-[(4-oxo-4-((4-(38-oxo-2,5,8,11,14,17,20,23,26,29,32,35-dodecaoxa-39-azahentetracontan-41-amido)phenyl]diazenyl)phenyl]amino)butyl]-pentanedioic acid, D-AG_{12} ................................................. 22
1.2.16 (2S,4S)-2-Amino-4-[(4-oxo-4-((4-((38-oxo-2,5,8,11,14,17,20,23,26,29,32,35-dodecaoxa-39-azahentetracontan-41-yl)amino)phenyl]diazenyl)phenyl]amino)-butyl]pentanedioic acid, D-AG_{12(445)} ................................................................................................................. 23

2 Spectral data ........................................................................................................................................................................... 24
2.1 N-[(2-Amino-9H-purin-6-yl)oxy]methyl]benzyl]pent-4-yname (3) ................................................................. 24
2.2 (2S,4S)-2-[(4-((4-((4-(2-(3-azidopropamido)acetamido)phenyl]diazenyl)phenyl)amino)-4-oxobutyl)]-4-((tert-butoxycarbonyl)amino)pentanedioic acid (14) .......................................................................................................................... 25
2.3 (2S,4S)-2-amino-4-[(4-((4-(3-((4-((2-amino-9H-purin-6-yl)oxy)methyl)benzyl)amino)-3-oxopropyl)-1H-1,2,3-triazol-1-yl)propanamido)acetamido)phenyl]diazenyl)phenyl]amino)-4-oxobutyl]pentanedioic acid, BGAG_{6} ....................................................................................................................... 26
2.4 (2S,4S)-2-Amino-4-[(4-((4-((4-((1-4-3-(4-((2-amino-9H-purin-6-yl)oxy)methyl)benzyl)amino)-3-oxopropyl)-1H-1,2,3-triazol-1-yl)-15-oxo-3,6,9,12-tetraoxa-16-azaoctadecan-18-amido)phenyl]diazenyl)phenyl]amino)-4-oxobutyl]pentanedioic acid, BGAG_{6} .......................................................................................................................... 27
2.5 (2S,4S)-2-Amino-4-[(4-((4-((4-1-3-((4-((2-amino-9H-purin-6-yl)oxy)methyl)benzyl)amino)-3-oxopropyl)-1H-1,2,3-triazol-1-yl)-27-oxo-3,6,9,12,15,18,21,24-octaoxa-28-azatricontan-30-amido)phenyl]diazenyl)phenyl]amino)-4-oxobutyl]pentanedioic acid, BGAG_{8} .......................................................................................................................... 28
2.6 (2S,4S)-2-Amino-4-[(4-((4-((4-((4-1-3-((4-((2-amino-9H-purin-6-yl)oxy)methyl)benzyl)amino)-3-oxopropyl)-1H-1,2,3-triazol-1-yl)-39-oxo-3,6,9,12,15,18,21,24,27,30,33,36-dodecaoxa-40-azadotetracontan-42-amido)phenyl]diazenyl)phenyl]amino)-4-oxobutyl]pentanedioic acid, BGAG_{12} 29
2.7 (2S,4S)-2-Amino-4-[(4-oxo-4-((4-((4-38-oxo-2,5,8,11,14,17,20,23,26,29,32,35-dodecaoxa-39-azahentetracontan-41-amido)phenyl]diazenyl)phenyl]amino)butyl]-pentanedioic acid, D-AG_{12} ............................................ 31
2.8 Dimethyl (2S,4S)-2-[(4-((4-((4-((1-(2-aminoethyl)amino)phenyl]diazenyl)phenyl)amino)-4-oxobutyl)-4-((tert-butoxycarbonyl)amino)phenyl)amino)-4-oxobutyl]-4-((tert-butoxycarbonyl)amino)pentanedioate .......................................................................................................................... 32
2.9 (2S,4S)-2-[(4-((4-((4-((2-aminoethyl)amino)phenyl]diazenyl)phenyl]amino)-4-oxobutyl)-4-((tert-butoxycarbonyl)amino)pentanedioic acid, (10) ........................................................................................................................................... 33
2.10 (2S,4S)-2-Amino-4-[(4-oxo-4-((4-((38-oxo-2,5,8,11,14,17,20,23,26,29,32,35-dodecaoxa-39-azahentetracontan-41-yl)amino)phenyl]diazenyl)phenyl]amino)butyl]-pentanedioic acid, D-AG_{12,445} ................................................................................................................ 34

3 Supporting Figures ........................................................................................................................................................................ 35
1 Experimental

1.1 General

Solvents for chromatography and reactions were purchased HPLC grade (except DMF was purchased from Acros, 99.8 %, extra dry over molecular sieves) or distilled over an appropriate drying reagent prior to use. If necessary, solvents were degassed either by freeze-pump-thaw or by bubbling N\textsubscript{2} through the vigorously stirred solution for several minutes. Unless otherwise stated, all other reagents were used without further purification from commercial sources.

Flash column chromatography was carried out on silica gel 60 (0.040–0.063 mm) purchased from Merck. Reactions and chromatography fractions were monitored by thin layer chromatography (TLC) on Merck silica gel 60 F254 glass plates. The plates were visualized under UV light at 254 nm.

NMR spectra were recorded in deuterated solvents on a BRUKER Avance III HD 400 (equipped with a CryoProbe™) instruments and calibrated to residual solvent peaks (\textsuperscript{1}H/\textsuperscript{13}C in ppm): DMSO-d\textsubscript{6} (2.50/39.52), Me\textsubscript{3}OD-d\textsubscript{4} (3.31/49.00). Multiplicities are abbreviated as follows: s = singlet, d = doublet, t = triplet, q = quartet, br = broad, m = multiplet. Spectra are reported based on appearance, not on theoretical multiplicities derived from structural information.

High-resolution electrospray (ESI) mass spectra were obtained on a Varian MAT 711 MS instrument operating in either positive or negative ionization modes.

LC-MS was performed on an Agilent 1260 Infinity HPLC System, MS-Agilent 1100 Series, Type: 1946D, Model: SL, equipped with an Agilent Zorbax Eclipse Plus C18 (100 x 4.6 mm, particle size 3.5 micron) RP column with a constant flow-rate of 2 mL/min, if not stated otherwise. Retention times (\(t_R\)) are given in minutes (min).

HPLC was performed on a Varian Prep Star HPLC System, Model SD-1 equipped with Varian Dynamax columns (RP-Analytical: Microsorb 60 C18, 250 x 4.6 mm, particle size 8 \(\mu\)m; RP-SemiPrep: Microsorb 60 C18, 250 x 21.4 mm, particle size 8 \(\mu\)m; RP-Prep: Microsorb 60 C18, 250 x 41.4 mm, particle size 8 \(\mu\)m). Prior to injection, samples were filtered through a syringe filter (Chromafil Xtra GF100/25, pore size 1 \(\mu\)m).
1.2 Synthesis of BGAGs

A. General procedure for attachment of the Azide-functionalized PEG-linker

In a schlenk flask, 8 or N-Boc-D-redAG0 10 (1.1 equiv.), Azido-(PEG)$_n$-NHS-ester (Baseclick, $n = 4$ (11, #BCL-001), $n = 8$ (12, #BCL-032), $n = 12$ (13, #BCL-033); 1.0 equiv.) and DIPEA (2.0 equiv.) were added to degassed, anhydrous DMF (0.5 mL) under N$_2$-atmosphere. The reaction mixture was stirred at r.t. while reaction progress was monitored by LCMS. Upon completion, the crude reaction mixture was purified by C18 reverse phase (RP) flash column chromatography (100/0 $\rightarrow$ 60/40 $= 1$ mM HCl/MeCN) or by RP-HPLC (MeCN/H$_2$O/formic acid $= 10/90/0.1 \rightarrow 80/20/0.1$ over 42 min). The product containing fractions were combined, concentrated in vacuo and freeze-dried to obtain the desired product.

B. General procedure for click reaction

In a schlenk flask, the reaction mixture was prepared with the corresponding azide (1.0 equiv.) and BG-alkyne (SI2.1) (1.1 eq) in degassed DMSO (2-4 mL) under N$_2$-atmosphere. Stock solutions of sodium ascorbate (NaAsc, 131 mM) and copper-(II)-sulfate pentahydrate (105 mM) were prepared separately in degassed water. 50 µL of each stock solution were mixed under N$_2$ to preform the catalytically active Cu$^+$ species and quickly transferred to the reaction mixture. The resulting reaction mixture was heated to 90 °C and reaction progress was monitored by LCMS. Upon completion, the crude product was purified by RP flash column chromatography (100/0 $\rightarrow$ 60/40 $= 1$ mM HCl/MeCN) or RP-HPLC (MeCN/H$_2$O/formic acid $= 10/90/0.1 \rightarrow 80/20/0.1$ over 42 min). The product containing fractions were combined, concentrated in vacuo and freeze-dried to obtain the desired product.

C. General procedure for Boc-deprotection:

In a falcon tube, neat TFA (250 µL) was added to the Boc-protected molecule and stirred at r.t. for 10 min. Diethylether (50 mL) was added and the resulting suspension was centrifuged (4000 rpm, 20 min, 4 °C). The supernatant was discarded, the solid was washed again with diethylether and finally dried under high vacuum to obtain the desired product.
1.2.1  \textit{N}-(4-(((2-Amino-9H-purin-6-yl)oxy)methyl)benzyl)pent-4-ynamide (3)

6-((4-(Aminomethyl)benzyl)oxy)-9H-purin-2-amine\textsuperscript{1} (BG) (382 mg, 1.41 mmol, 1.2 equiv.), 4-pentynoic acid (2) (115 mg, 1.17 mmol, 1.0 equiv.), HBTU (489 mg, 1.29 mmol, 1.1 equiv.) and DIPEA (302 mg, 2.34 mmol, 409 \( \mu \)L, 2.0 equiv.) were dissolved in DMF (5 mL). Reaction progress was monitored by LCMS and after completion, the crude reaction mixture was subjected to RP-HPLC (MeCN/H\textsubscript{2}O/FA = 10/90/0.1 \( \rightarrow \) 80/20/0.1 over 40 min). The product containing fractions were combined, concentrated \textit{in vacuo} and dried under high vacuum to obtain the product BG-alkyne (3) (178 mg, 0.508 mmol) as a white powder in 43\% yield.

NMR spectroscopy revealed two rotamers, proven by heating the NMR sample to 50 °C and merging of the spectroscopic signals (data not shown). Peaks are reported for the major rotamer.

\textit{\textsuperscript{1}H NMR} (400 MHz, DMSO-\textsubscript{d}6): \( \delta \) [ppm] = 8.45–8.34 (m, 1H), 8.13 (s, 1H), 8.10 (s, 1H), 7.47 (d, \( J = 8.4 \) Hz, 2H), 7.29 (d, \( J = 8.4 \) Hz, 2H), 6.59 (br s, 2H), 5.48 (s, 2H), 4.32–4.21 (m, 2H), 2.78 (m, 1H), 2.43–2.28 (m, 4H).

\textit{\textsuperscript{13}C NMR} (101 MHz, DMSO-\textsubscript{d}6): \( \delta \) [ppm] = 170.3, 159.2, 159.1, 155.0, 141.0, 139.5, 134.7, 128.7, 127.3, 126.4, 83.8, 71.4, 67.2, 41.9, 34.2, 14.3.

\textbf{HRMS (ESI)}: calc. for C\textsubscript{18}H\textsubscript{19}N\textsubscript{6}O\textsubscript{2}\textsuperscript{+} (M+H): \( \approx \) 351.1564, found: 351.1562.

\textbf{UV/Vis} (LCMS): \( \lambda \text{max}_1 = 196 \text{ nm}, \lambda \text{max}_2 = 212 \text{ nm}, \lambda \text{max}_3 = 287 \text{ nm}.

\( t_R \) (LCMS; MeCN/H\textsubscript{2}O/formic acid = 10/90/0.1 \( \rightarrow \) 90/10/0.1 over 7 min) = 1.955 min.
1.2.2 \( N\)-(4-(((2-Amino-9H-purin-6-yl)oxy)methyl)benzyl)-4-(11,12-dehydrodibenzo[b,f]azocin-5(6H)-yl)-4-oxobutanamide (5)

![Chemical structure of 5](image)

6-((4-(Aminomethyl)benzyl)oxy)-9H-purin-2-amine\(^1\) (BG) (6.7 mg, 24.9 \( \mu \text{mol}, 1.0 \text{ equiv.}), DBCO-NHS-ester (Jena Bioscience, CLK-A133-25, 4) (10.0 mg, 24.9 \( \mu \text{mol}, 1.0 \text{ equiv.}) and DIPEA (6.4 mg, 49.8 \( \mu \text{mol}, 8.7 \mu \text{L}, 2.0 \text{ equiv.}) were dissolved in DMSO (0.5 mL). Reaction progress was monitored by LCMS and after completion the crude reaction mixture was subjected to RP-HPLC (MeCN/H\(_2\)O/formic acid = 5/95/0.1 \( \rightarrow \) 80/20/0.1 over 40 min). The product containing fractions were combined, concentrated \textit{in vacuo} and dried under high vacuum to obtain 5 (1.0 mg, 1.79 \( \mu \text{mol}) in 7\% yield. The low yield can be attributed to residual water in the used DMSO as the corresponding DBCO-acid was obtained as the main product.

\textbf{HRMS (ESI)}: calc. for \( C_{32}H_{28}N_{7}O_{3} \) \([M+H]^+\): 558.2248, found: 558.2254.

\textbf{UV/Vis (LCMS)}: \( \lambda_{\text{max}} \) = 290 nm.

\( t_R \) (LCMS; MeCN/H\(_2\)O/formic acid = 10/90/0.1 \( \rightarrow \) 90/10/0.1 over 7 min) = 3.118 min.
1.2.3 (25,4S)-2-[(4-((E)-(4-(2-Aminoacetamido)phenyl)diazenyl)phenyl)amino]-4-oxobutyl)-4-((tert-butoxycarbonyl)amino)pentanedioic acid (6)

![Chemical Structure of Compound 6]

6 was prepared according to a literature procedure and analytical data matched the one reported.\(^2\)

\(^1\)H-NMR (400 MHz, DMSO-d_6) δ [ppm] = 10.29 (s, 1H), 7.93–7.75 (m, 9H), 6.60 (d, J = 7.8 Hz, 1H), 3.90 (q, J = 8.1 Hz, 1H), 3.78 (s, 2H), 2.44–2.25 (m, 3H), 1.88–1.42 (m, 6H), 1.36 (s, 9H).

\(^13\)C NMR (101 MHz, DMSO-d_6) δ [ppm] = 176.3, 174.0, 171.5, 165.9, 155.1, 148.0, 147.4, 142.2, 140.9, 123.5, 123.4, 119.4, 119.2, 77.9, 55.0, 52.0, 41.6, 40.1, 36.5, 30.9, 28.2, 23.0.

HRMS (ESI): calc. for C_{28}H_{37}N_{6}O_{8} \[M+H]\(^+\): 585.2667, found: 585.2673.

UV/VIS (LCMS): \(\lambda_{\text{max}} (\pi \rightarrow \pi^*)\) = 368 nm.

t_R (LCMS, MeCN/H_2O/formic acid = 90/10/0.1 → 10/90/0.1 over 7 min) = 2.418 min.
1.2.4 (25S,4S)-2-(4-((4-((E)-(4-((2-(3-azidopropanamido)acetamido)phenyl)diazenyl)phenyl)amino)-4-oxobutyl)-4-((tert-butoxycarbonyl)amino)pentanediioic acid (14)

A schlenk flask was charged with 8 (10 mg, 17 µmol, 1.0 equiv.), HBTU (7.2 mg, 19 µmol, 1.1 equiv.) and 3-azidopropionic acid\(^3\) (3.0 mg, 16 µmol, 1.5 equiv.) under a N\(_2\)-atmosphere. Degassed, anhydrous DMF (1 mL) was added and the reaction mixture was cooled to 0 °C before DIPEA (6.0 µL, 34 µmol, 2.0 equiv.) was added dropwise. The reaction mixture was allowed to warm to r.t. and reaction progress was monitored by LCMS. Upon completion, the crude reaction mixture was purified by RP-HPLC (10/90/0.1 → 80/20/0.1 = MeCN/H\(_2\)O/formic acid over 45 min). The product containing fractions were combined, concentrated in vacuo and freeze-dried to obtain 10 mg (15 µmol) of 14 as a yellow solid in 88% yield.

\(^1\)H NMR (400 MHz, DMSO-d\(_6\)) \(\delta\) [ppm] = 10.34 (s, 1H), 10.25 (s, 1H), 8.43 (t, \(J = 5.8\) Hz, 1H), 7.98–7.71 (m, 8H), 3.96 (d, \(J = 5.7\) Hz, 2H), 3.89 (t, \(J = 7.3\) Hz, 1H), 3.53 (t, \(J = 6.4\) Hz, 2H), 2.67 (s, 1H), 2.43–2.23 (m, 4H), 1.86–1.42 (m, 6H), 1.36 (s, 9H).

HRMS (ESI): calc. for C\(_{31}\)H\(_{38}\)N\(_9\)O\(_9\) [M-H]: 680.2798, found: 680.2798.

\(t_R\) (RP-HPLC, MeCN/H\(_2\)O/formic acid = 10/90/0.1 → 80/20/0.1 over 42 min)= 26.2 min (trans)
1.2.5 (25,4S)-2-Amino-4-(4-(((E)-4-(2-(3-(4-(4-(((2-amino-9H-purin-6-yl)oxy)methyl)benzyl)amino)-3-oxopropyl)-1H-1,2,3-triazol-1-yl)propanamido)acetamido)-phenyl)diazenyl)phenyl)amino)-4-oxobutyl)pentanedioic acid, BGAG₀

BGAG₀ was prepared according to general procedures B and C.

Amounts:

3 (5.8 mg, 17 µmol, 1.1 equiv.)

14 (10 mg, 15 µmol, 1.0 equiv.)

yield: 3.3 mg (3.5 µmol, 23% over two steps), yellow solid.

¹H NMR (400 MHz, DMSO-d₆) δ 10.52 (s, 1H), 10.33 (s, 1H), 10.27 (s, 1H), 8.51–8.24 (m, 3H), 7.96–7.59 (m, 8H), 7.52 (dd, J = 8.9, 3.1 Hz, 1H), 7.41 (m, 2H), 7.23 (t, J = 9.0 Hz, 3H), 7.18–7.06 (m, 1H), 6.98 (s, 1H), 6.82 (t, J = 7.4 Hz, 1H), 6.29 (br s, 2H), 5.42 (br s, 2H), 4.52 (t, J = 7.0 Hz, 2H), 4.27 (t, J = 4.9 Hz, 2H), 3.94 (d, J = 5.7 Hz, 2H), 3.60 (s, 1H), 3.16 (d, J = 4.0 Hz, 1H), 2.90–2.83 (m, 2H), 2.79 (t, J = 6.8 Hz, 2H), 2.67 (p, J = 1.7 Hz, 1H), 2.41–2.31 (m, 3H), 1.88–1.33 (m, 6H).

HRMS (ESI): calc. for C₄₄H₄₈N₁₅O₉⁻ [M-H]⁻: 930.3765, found: 930.3770.

tᵣ (RP-HPLC, MeCN/H₂O/formic acid = 10/90/0.1 → 80/20/0.1 over 42 min) = 18.4 min (trans, before Boc-deprotection).

UV/VIS (LCMS): λₘₐₓ (π → π⁺) = 368 nm.

tᵣ (LCMS, MeCN/H₂O/formic acid = 90/10/0.1 → 10/90/0.1 over 10 min, flow: 1 ml/min) = 3.960 min.
1.2.6 (25S,4S)-2-((4-((E)-(4-((1-Azido-15-oxo-3,6,9,12-tetraoxa-16-azaoctadecan-18-yl)amino)phenyl)diazenyl)phenyl)amino)-4-oxobutyl)-4-((tert-butoxycarbonyl)-amino)pentanedioic acid (15)

15 was prepared according to general procedure A.

Amounts:
N₃-PEG₄-NHS-ester (#BCL-001, 8.6 mg, 22 µmol, 1.1 equiv.)
8 (14.3 mg, 24 µmol, 1.0 equiv.)
DIPEA (7.7 µL, 44 µmol, 2.0 equiv.)

yield: 18.0 mg (21 µmol, 86%), yellow solid.

HRMS (ESI): calc. for C₃₉H₅₄N₉O₁₃ [M-H]⁻: 856.3847, found: 856.3844.

UV/VIS (LCMS): \( \lambda_{\text{max}} (\pi \rightarrow \pi^*) = 368 \text{ nm} \).

t<sub>R</sub> (LCMS, MeCN/H₂O/formic acid = 90/10/0.1 \rightarrow 10/90/0.1 over 10 min) = 5.130 min.
1.2.7 (25,4S)-2-Amino-4-{4-[(4-{[(E)-4-[(4-{3-[(4-((2-amino-9H-purin-6-yl)oxy)methyl]benzyl)amino]-3-oxopropyl]-1H,1,2,3-triazol-1-yl]-15-oxo-3,6,9,12-tetraoxa-16-aza-octadecan-18-amido)phenyl]diazethyl}phenylamino]-4-oxobutyl]-pentanedioic acid, BGAG₄

\[ \text{BGAG₄} \]

BGAG₄ was prepared according to general procedures B and C.

Amounts:

3 (7.8 mg, 23 µmol, 1.1 equiv.)
15 (18 mg, 21 µmol, 1.0 equiv)

yield: 5.1 mg (5 µmol, 24% over two steps).

\(^1H\) NMR (400 MHz, DMSO-\text{d}_6) \( \delta \) [ppm] = 10.58 (s, 1H), 10.33 (s, 1H), 10.30 (s, 1H), 8.37 (t, \( J = 6.2 \) Hz, 2H), 8.28 (t, \( J = 5.8 \) Hz, 2H), 7.89–7.69 (m, 12H), 7.23 (d, \( J = 7.9 \) Hz, 2H), 7.14 (d, \( J = 7.9 \) Hz, 2H), 6.28 (s, 2H), 4.44 (t, \( J = 5.1 \) Hz, 4H), 4.23 (d, \( J = 5.9 \) Hz, 2H), 3.93 (d, \( J = 5.7 \) Hz, 2H), 3.77 (t, \( J = 5.3 \) Hz, 3H), 3.62 (t, \( J = 6.5 \) Hz, 2H), 3.54–3.44 (m, 12H), 2.86 (t, \( J = 7.6 \) Hz, 2H), 2.45–2.30 (m, 5H), 1.97–1.72 (m, 3H), 1.70–1.39 (m, 6H).

HRMS (ESI): calc. for \( C_{52}H_{66}N_{15}O_{13}^+ \) [M+H]^+: 1108.4959, found: 1108.4943.

UV/VIS (LCMS): \( \lambda_{\text{max}} (\pi \to \pi^*) = 368 \) nm.

\( t_a \) (LCMS, MeCN/H₂O/formic acid = 90/10/0.1 → 10/90/0.1 over 10 min) = 2.927 min.
1.2.8  \((25S,45S)-2-(4-((E)-(4-((1-Azido-27-oxo-3,6,9,12,15,18,21,24-octaoxa-28-azatriacontan-30-yl)amino)phenyl)diazenyl)-phenyl)amino)4-oxobutyl)-4-((tert-butoxycarbonyl)-amino)pentanedioic acid (16)\)

\[
\begin{align*}
\text{HOOC} & \\
\text{NH} & \\
\text{NH} & \\
\text{O} & \\
\text{N} & \\
\text{N} & \\
\text{N} & \\
\text{N} & \\
\text{N} & \\
\text{NH} & \\
\text{Boc} & \\
\text{COOH} & \\
\text{B} & \\
\text{O} & \\
\text{N} &
\end{align*}
\]

16 was prepared according to general procedure A.

Amounts:

N\textsubscript{3}-PEG\textsubscript{8}-NHS-ester (#BCL-032, 10.0 mg, 17.7 \mu mol, 1.0 equiv.)

8 (11.4 mg, 19.5 \mu mol, 1.1 equiv.)

DIPEA (6.2 \mu L, 35.4 \mu mol, 2.0 equiv.)

yield: 18.0 mg (17 \mu mol, 89%), yellow solid.

**HRMS (ESI):** calc. for C\textsubscript{47}H\textsubscript{69}N\textsubscript{9}O\textsubscript{17} \^{2-} [M-2H]\textsuperscript{2-}: 515.7411, found: 515.7407.

**UV/VIS (LCMS):** \(\lambda_{\text{max}} (\pi \rightarrow \pi^*) = 368 \text{ nm} \).

\( t_r \) (LCMS, MeCN/H\textsubscript{2}O/formic acid = 90/10/0.1 \rightarrow 10/90/0.1 over 10 min) = 4.998 min.
1.2.9 (2S,4S)-2-Amino-4-(4-((E)-(4-1-(4-(3-(4-((2-amino-9H-purin-6-yl)oxy)methyl)-benzyl)amino)-3-oxopropyl)-1H-1,2,3-triazol-1-yl)-27-oxo-3,6,9,12,15,18,21,24-octa-oxo-28-azatriacontan-30-amido)phenyl)diazenyl)phenylamino)-4-oxobutyl)pentane-dioic acid, BGAG₈

BGAG₈ was prepared according to general procedures B and C.

Amounts:

3 (7.1 mg, 21 µmol, 1.2 equiv.)

16 (18 mg, 17 µmol, 1.0 equiv.)

yield: 9.6 mg (7.5 µmol, 44% over two steps), yellow solid.

H NMR (400 MHz, DMSO-d₆) δ 10.91 (s, 1H), 10.32 (s, 1H), 10.29 (s, 1H), 8.43–8.20 (m, 5H), 8.09 (s, 1H), 7.89–7.72 (m, 10H), 7.23 (d, J = 7.7 Hz, 2H), 7.14 (d, J = 7.7 Hz, 2H), 6.55 (s, 2H), 4.73 (s, 1H), 4.50–4.39 (m, 4H), 4.23 (d, J = 6.3 Hz, 2H), 3.93 (d, J = 5.8 Hz, 2H), 3.77 (t, J = 5.3 Hz, 2H), 3.62 (t, J = 6.6 Hz, 2H), 3.49 (d, J = 4.6 Hz, 28H), 2.86 (t, J = 7.7 Hz, 2H), 2.46–2.31 (m, 6H), 2.10–1.96 (m, 1H), 1.85 (dt, J = 14.2, 7.0 Hz, 1H), 1.58 (d, J = 6.3 Hz, 5H).

HRMS (ESI): calc. for C₆₀H₈₂N₁₅O₁₇⁺ [M+H]⁺: 1284.6008, found: 1284.6004.

UV/VIS (LCMS): λ_{max} (π → π*)= 368 nm.

tₚ (LCMS, MeCN/H₂O/formic acid = 90/10/0.1 → 10/90/0.1 over 10 min) = 3.059 min.
1.2.10 (25S)-2-\((4-((E)-(4-(1-Azido-39-oxo-3,6,9,12,15,18,21,24,27,30,33,36-dodecaoxa-40-azadotetracontan-42-amido)phenyl)diazeneyl)phenyl)amino)-4-oxobutyl)-4-((tert-butoxycarbonyl)amino)pentanedioic acid (17)

\[
\begin{align*}
\text{\textbf{17} was prepared according to general procedure A.} \\
\text{Amounts:} \\
N_3\text{-}\text{PEG}_{12}\text{-}N\text{HS-Ester (Baseclick \#BCL-033, 10.0 mg, 13.5 \text{\textmu}mol, 1.0 equiv.)} \\
8 (8.7 mg, 14.8 \text{\textmu}mol, 1.1 equiv.) \\
\text{DIPEA (3.5 mg, 27.0 \text{\textmu}mol, 4.7 \muL, 2.0 equiv.)} \\
\text{yield: 13.0 mg (10.8 \text{\textmu}mol, 80\%), yellow solid.} \\
\text{HRMS (ESI): calcul. for } C_{55}H_{85}N_{9}O_{21}^{2-} [M-2H]^2+: 603.7936, \text{ found: } 603.7937. \\
\text{UV/Vis (LCMS): } \lambda_{\text{max}} (\pi \rightarrow \pi^*) = 368 \text{ nm.} \\
\text{t}_R (LCMS; \text{MeCN/H}_2\text{O/formic acid} = 10/90/0.1 \rightarrow 90/10/0.1 \text{ over } 7 \text{ min}) = 3.232 \text{ min.}
\end{align*}
\]
1.2.11 (25,45)-2-Amino-4-(4-((4-((E)-4-(1-((4-((2-amino-9H-purin-6-
yl)oxy)methyl)benzyl)amino)-3-oxopropyl)-1H-1,2,3-triazol-1-yl)-39-oxo-
3,6,9,12,15,18,21,24,27,30,33,36-dodecaoxa-40-azadotetracontan-42-
amido)phenyl)diazenyl)phenyl)amino)-4-oxobutyl)pentanedioic acid, BGAG₁₂

```
\[ \text{HOOC} \quad \text{NH}_2 \quad \text{COOH} \]
\[ \text{N} = \text{N} \quad \text{H}_2 \text{N} \quad \text{N} \quad \text{H} \]
\[ \text{O} \quad \text{N} \quad \text{N} \quad \text{N} \quad \text{NH} \quad \text{NH} \]
```

BGAG₁₂ was prepared according to general procedures B and C.

Amounts:

3 (4.2 mg, 11.9 µmol, 1.2 equiv.)

17 (12.0 mg, 9.9 µmol, 1.0 equiv.)

yield: 6.8 mg (7.06 µmol, 65% over two steps), orange solid.

\[^1\text{H NMR}\] (400 MHz, DMSO-d₆): \( \delta \) [ppm] = 10.30 (s, 1H), 10.26 (s, 1H), 8.47 (br s, 1H), 8.81 (t, \( J = 6.0 \) Hz, 1H), 8.36–8.16 (m, 3H), 7.93–7.68 (m, 8H), 7.48 (d, \( J = 6.0 \) Hz, 2H), 7.24 (d, \( J = 6.0 \) Hz, 2H), 6.88–6.74 (m, 1H), 5.53 (br s, 2H), 4.44 (t, \( J = 5.2 \) Hz, 2H), 4.27 (d, \( J = 6.0 \) Hz, 2H), 3.94 (d, \( J = 6.0 \) Hz, 2H), 3.63 (br s, 2H), 3.41 (m, 4H), 2.86 (t, \( J = 8.0 \) Hz, 2H), 2.62–2.55 (m, 2H), 2.46–2.28 (m, 7H), 2.16–1.91 (m, 2H), 1.90–1.74 (m, 1H), 1.66–1.51 (m, 4H), 1.48–1.28 (m, 2H).

\[ \text{HRMS (ESI)}: \text{calc. for C}_{68}\text{H}_{99}\text{N}_{15}\text{O}_{21\text{²}}\text{[M+2H]}^{2\text{²}}: 730.8565, \text{found: 730.8564.} \]

\[ \text{UV/Vis (LCMS): } \lambda_{\text{max}} (\pi \to \pi^*) = 369 \text{ nm.} \]

\[ t_{R} \text{ (LCMS; MeCN/H}_2\text{O/formic acid = 10/90/0.1 } \to 90/10/0.1 \text{ over 7 min) } = 2.463 \text{ min.} \]
1.2.12 (25,4S)-2-(4-(((E)-4-((2-aminoethyl)amino)phenyl)diazenyl)phenyl)amino)-4-oxobutyl)-4-((tert-butoxycarbonyl)amino)pentanedioic acid (10)

Dimethyl (25,4S)-2-(4-(((E)-4-((aminophenyl)diazenyl)phenyl)amino)-4-oxobutyl)-4-((tert-butoxycarbonyl)amino)pentanedioate\(^2\) (200 mg, 0.360 mmol, 1.0 equiv.) and Fmoc-2-aminoacetaldehyde\(^4\) (101 mg, 0.360 mmol, 1.0 equiv.) were dissolved in DCE (10 mL) and one drop of acetic acid was added. Sodium triacetoxyborohydride (270 mg, 1.28 mmol, 3.6 equiv.) was added portionwise and the reaction mixture was stirred at r.t. for 4.5 h. The reaction mixture was quenched and subsequently washed with sat. aq. NaHCO\(_3\) (3x) before the organic layer was concentrated in vacuo. The residue was redissolved in DMF (47.5 mL), piperidine (2.5 mL) was added and the deprotecting reaction was stirred overnight. The reaction mixture was concentrated in vacuo, the residue was redissolved in EtOAc, washed with sat. aq. NaHCO\(_3\) (2x) and brine (sat.) before the organic layer was dried over MgSO\(_4\). The solvent was removed in vacuo before purification by flash column chromatography (90/10/1 = DCM/MeOH/TEA) followed by RP column chromatography (100/0 → 60/40 = 1mM HCl/MeCN). The product containing fractions were combined, concentrated in vacuo and freeze-dried to obtain the intermediate bis-methylester dimethyl (25,4S)-2-(4-(((E)-4-((2-aminoethyl)amino)phenyl)diazenyl)phenyl)amino)-4-oxobutyl)-4-((tert-butoxycarbonyl)amino) pentanedioate as its red-orange HCl salt (84 mg, 0.13 mmol) in 36% yield over 2 steps.

\(^1\)H-NMR (400 MHz, MeOD-\(d_4\)) \(\delta\) [ppm] = 7.82–7.66 (m, 6H), 6.80 (d, \(J = 8.9\) Hz, 2H), 4.16 (dd, \(J = 8.4, 6.2\) Hz, 1H), 3.71–3.65 (m, 6H), 3.55 (t, \(J = 6.1\) Hz, 2H), 3.18 (t, \(J = 6.8\) Hz, 2H), 2.52 (p, \(J = 6.9\) Hz, 1H), 2.44–2.35 (m, 2H), 2.01–1.90 (m, 2H), 1.73–1.57 (m, 3H), 1.42 (s, 9H), 1.29 (q, \(J = 6.6, 5.9\) Hz, 1H).

\(^13\)C-NMR (101 MHz, MeOH-\(d_4\)) \(\delta\) [ppm] = 177.3, 174.3, 174.0, 157.9, 152.8, 149.7, 145.6, 141.5, 126.5, 123.7, 121.2, 113.7, 80.7, 53.4, 52.7, 52.4, 43.5, 41.7, 39.8, 37.6, 34.8, 32.6, 28.7, 24.2.

HRMS (ESI): calc. for C\(_{30}\)H\(_{43}\)O\(_2\)N\(_6\)\(^+\) [M+H]\(^+\): 599.3188, found: 599.3191.

UV/VIS (LCMS): \(\lambda_{\max} = 412\) nm.

\(t_h\) (LCMS, MeCN/H\(_2\)O/formic acid = 90/10/0.1 → 10/90/0.1 over 7 min) = 2.915 min.

In a round bottom flask, dimethyl (25,4S)-2-(4-(((E)-4-((2-aminoethyl)amino)phenyl)diazenyl)phenyl)amino)-4-oxobutyl)-4-((tert-butoxycarbonyl)amino) pentanedioate (84 mg, 0.13 mmol, 1.0 equiv.) was dissolved in a mixture of H\(_2\)O (3.7 mL) and THF (7.3 mL) before lithium hydroxide (78 mg, 3.3 mmol, 25 equiv.) was added as a solid at 0 °C in one portion. The reaction was stirred for 2 h at 0 °C,
before it was neutralized by addition of formic acid (0.12 mL, 3.3 mmol, 25 equiv.). The THF was removed *in vacuo* before the aqueous phase was subjected to RP column chromatography (100/0 → 75/25 = 1 mM HCl/MeCN). The product containing fractions were combined, concentrated *in vacuo* and freeze-dried to obtain 10 as its red HCl salt (33.5 mg, 55 µmol) in 43% yield.

$^1$H-NMR (400 MHz, DMSO-$d_6$) δ [ppm] 10.18 (s, 1H), 7.80–7.64 (m, 6H), 6.82 (s, 1H), 6.75 (d, J = 8.6 Hz, 2H), 6.51 (d, J = 7.7 Hz, 1H), 3.91 (q, J = 8.2 Hz, 1H), 3.46–3.36 (m, 2H), 3.02 (t, J = 6.3 Hz, 2H), 2.47–2.37 (m, 1H), 2.32 (t, J = 7.2 Hz, 2H), 1.72–1.44 (m, 5H), 1.37 (s, 9H), 1.34 (s, 1H).

$^{13}$C-NMR (101 MHz, DMSO-$d_6$) δ [ppm] = 176.9, 174.7, 171.8, 155.3, 151.5, 148.2, 143.8, 141.3, 125.2, 123.0, 119.7, 112.4, 78.2, 52.9, 42.4, 40.7, 38.3, 37.0, 35.8, 31.6, 28.7, 23.6.

HRMS (ESI): calc. for C$_{28}$H$_{39}$O$_7$N$_6$ $^+\ [M+H]^+$: 571.2875, found: 571.2877.

UV/VIS (LCMS): $\lambda_{\text{max}}$ = 412 nm.

$t_R$ (LCMS, MeCN/H$_2$O/formic acid = 90/10/0.1 → 10/90/0.1 over 7 min) = 2.438 min.
1.2.13  \((25S,4S)-2-(4-((E)-4-(((1\text{-azido-39-oxo-3,6,9,12,15,18,21,24,27,30,33,36-dodecaoxa-40-azadotetracontan-42-yl)amino})phenyl)diazenyl)phenyl)amino)-4-oxobutyl)-4-((\text{tert-butoxycarbonyl})amino)pentanedioic acid, (18)\)

\[
\begin{align*}
\text{N}_3\text{-PEG}_{12}\text{-NHS-Ester (Baseclick \#BCL-033, 10.0 mg, 13.5 \mu mol, 1.0 equiv.)} \\
\text{10 (8.5 mg, 14.9 \mu mol, 1.1 equiv.)} \\
\text{DIPEA (3.5 mg, 27.0 \mu mol, 4.7 \mu L, 2.0 equiv.)} \\
\text{yield: 14.0 mg (11.7 \mu mol, 87%), red-orange solid.}
\end{align*}
\]

HRMS (ESI): calc. for \(C_{55}H_{87}N_{9}O_{20}^{2-}\) [M-2H]^{2-}: 596.8039, found: 596.8035.

UV/Vis (LCMS): \(\lambda_{\text{max}} = 412\) nm.

t_{R} (LCMS; MeCN/H\text{O}/formic acid = 10/90/0.1 \rightarrow 90/10/0.1 \text{ over 10 min}) = 5.117\) min.
1.2.14 (25S,4S)-2-amino-4-(4-(4-((E)-4-((1-(8-(4-(((2-amino-9H-purin-6-yl)oxy)methyl)benzyl)amino)-4-oxobutanoyl)-8,9-dihydro-1H-dibenzo[b,f][1,2,3]triazolo[4,5-d]azocin-1-yl)-39-oxo-3,6,9,12,15,18,21,24,27,30,33,36-dodecaoxa-40-azadotetracontan-42-yl)amino)phenyl)diazerylphenyl)amino)-4-oxobutyl)pentanedioic acid, BGAG\textsubscript{12,460}

In a round bottom flask, 5 (1.0 mg, 1.79 µmol) and 18 (2.1 mg, 1.79 µmol) were combined and dissolved in MeOH. After stirring at r.t. for 30 min all starting material was consumed according to LCMS and all volatiles were removed in vacuo to obtain the crude protected triazole. The solid was treated with 0.35 mL neat TFA for 10 min at r.t. before Et\textsubscript{2}O was added and the suspension was subjected to sedimentation (4,000 rpm, r.t., 20 min) to collect a deep-red solid, which was washed again with Et\textsubscript{2}O and dried under HV to obtain 1.2 mg (1.03 µmol) BGAG\textsubscript{12,460} in 58% yield (over 2 steps).

HRMS (ESI): calc. for C\textsubscript{82}H\textsubscript{110}N\textsubscript{16}O\textsubscript{21}\textsuperscript{2+} (M+2H)	extsuperscript{2+}: 827.4010, found: 827.4015.

UV/Vis (LCMS): $\lambda_{\text{max}} = 413$ nm.

t\textsubscript{R} (LCMS; MeCN/H\textsubscript{2}O/formic acid = 10/90/0.1 $\rightarrow$ 90/10/0.1 over 7 min) = 2.601 min.
1.2.15 (25,4S)-2-Amino-4-{4-oxo-4-(4-(E)-(4-(38-oxo-2,5,8,11,14,17,20,23,26,29,32,35-dodecaoxa-39-azahentetracontan-41-amido)phenyl)diazetyl)phenyl)amino)butyl)-pentanedioic acid, D-AG$_{12}$

![Chemical Structure]

D-AG$_{12}$ was prepared according to general procedures A and C.

Amounts:

Methyl-PEG$_{12}$-NHS-ester (Thermo Scientific #22685, 9.7 mg, 14 µmol, 1.0 equiv.)

8 (9.1 mg, 16 µmol, 1.1 equiv.)

DIPEA (4.9 µL, 28 µmol, 2 equiv.)

yield: 8.0 mg (7.6 µmol, 54% over two steps), orange solid.

$^1$H-NMR (400 MHz, DMSO-$d_6$) δ [ppm] = 10.31 (s, 1H), 10.27 (s, 1H), 8.27 (t, $J$ = 5.8 Hz, 1H), 7.88–7.76 (m, 8H), 3.93 (d, $J$ = 5.7 Hz, 2H), 3.63 (t, $J$ = 6.5 Hz, 5H), 3.50 (s, 45H), 3.23 (s, 4H), 2.61 (s, 1H), 2.43 (t, $J$ = 6.5 Hz, 5H), 2.36 (t, $J$ = 7.0 Hz, 2H), 1.83 (s, 1H), 1.60 (p, $J$ = 11.4, 10.7 Hz, 3H), 1.48–1.39 (m, 1H).

HRMS (ESI): calc. for C$_{49}$H$_{79}$N$_6$NaO$_{19}$$^{2+}$ [M+Na+H]$^{2+}$: 539.2643, found: 539.2639.

UV/VIS (LCMS): $\lambda_{max}$ ($\pi \to \pi^*$) = 368 nm.

t$_R$ (LCMS, MeCN/H$_2$O/formic acid = 90/10/0.1 → 10/90/0.1 over 10 min) = 3.346 min.
1.2.16 (25,4S)-2-Amino-4-(4-oxo-4-(((4-((38-oxo-2,5,8,11,14,17,20,23,26,29,32,35-dodecaoxa-39-azahentetracontan-41-yl)amino)phenyl)diazenyl)phenyl)amino)-butyl)pentanedioic acid, D-AG$_{12(445)}$

\[
\begin{align*}
\text{D-AG}_{12(445)} & \text{ was prepared according to general procedures A and C.}
\end{align*}
\]

**Amounts:**

Methyl-PEG12-NHS-ester (Thermo Scientific, #22685, 9.8 mg, 14 µmol, 1.0 equiv.)

18 (9.0 mg, 16 µmol, 1.1 equiv.)

yield: 12 mg, (12 µmol, 73% over two steps), red solid.

$^1$H NMR (400 MHz, DMSO-d$_6$) δ [ppm] = 10.17 (s, 1H), 8.03 (t, J = 5.5 Hz, 1H), 7.71 (dt, J = 12.6, 9.1 Hz, 6H), 6.70 (d, J = 8.8 Hz, 2H), 6.62 (s, 1H), 3.62 (dt, J = 18.7, 7.1 Hz, 4H), 3.49 (d, J = 3.0 Hz, 50H), 2.60 (q, J = 7.3 Hz, 1H), 2.34 (q, J = 6.6 Hz, 5H), 1.95–1.74 (m, 2H), 1.68–1.37 (m, 5H).

HRMS (ESI): calc. for C$_{49}$H$_{81}$N$_6$NaO$_{18}^{2+}$ [M+Na+H]$^+$: 532.2747, found: 532.2743.

UV/VIS (LCMS): $\lambda_{max} = 412$ nm.

$t_r$ (LCMS, MeCN/H$_2$O/formic acid = 90/10/0.1 → 10/90/0.1 over 10 min) = 3.397 min.
2 Spectral data

2.1 \( N-(4-(((2\text{Amino}-9H\text{-purin}-6\text{-yl})\text{oxy})\text{methyl})\text{benzyl})\text{pent-4-ynamide (3)} \)
2.2 \((2S,4S)-2-(4-((4-(E)-(4-(2-(3-azidopropanamido)acetamido)phenyl)diazenyl)phenyl)-amino)-4-oxobutyl)-4-((\textit{tert}-butoxycarbonyl)amino)pentanedioic acid (14)\)
2.3 (2S,4S)-2-amino-4-(4-((4-((E)-(4-((2-(3-(4-((4-(((2-amino-9H-purin-6-yl)oxy)methyl)benzyl)amino)-3-oxopropyl)-1H-1,2,3-triazol-1-yl)propanamido)acetamido)phenyl)diazanyl)phenyl)amino)-4-oxobutyl)pentanedioic acid, BGAG₀
2.4 (2S,4S)-2-Amino-4-(4-((4-((E)-(4-(1-(3-((4-((2-amino-9H-purin-6-yloxy)methyl)benzyl)amino)-3-oxopropyl)-1H-1,2,3-triazol-1-yl)-15-oxo-3,6,9,12-tetraoxa-16-azaoctadecan-18-amido)phenyl)diazenyl)phenyl)amino)-4-oxobutyl)pentanedioic acid, BGAG₄
2.5 (2S,4S)-2-Amino-4-(4-((4-(4-(4-(3-((4-((2-amino-9H-purin-6-yl)oxy)methyl)benzyl)amino)-3-oxopropyl)-1H-1,2,3-triazol-1-yl)-27-oxo-3,6,9,12,15,18,21,24-octaoxa-28-azatriacontan-30-amido)phenyl)diazene)phenylamino)-4-oxobutyl)pentanedioic acid, BGAG₈
2.6 (2S,4S)-2-Amino-4-(4-((4-((E)-(4-((3-(4-((((2-amino-9H-purin-6-yl)oxy)methyl)benzyl)amino)-3-oxopropyl)-1H-1,2,3-triazol-1-yl)-39-oxo-3,6,9,12,15,18,21,24,27,30,33,36-dodecaoxa-40-azadotetracontan-42-amido)phenyl)diazeny)phenyl)amino)-4-oxobutyl)pentanedioic acid, BGAG_{12}
2.7 (2S,4S)-2-amino-4-(4-oxo-4-((4-(E)-(4-(38-oxo-2,5,8,11,14,17,20,23,26,29,32,35-dodecaoxa-39-azahentetracontan-41-amido)phenyl)diazenyl)phenyl)amino)butyl)pentanedioic acid, D-AG_{12}
2.8 Dimethyl (2S,4S)-2-[(4-[(E)-(4-((2-aminoethyl)amino)phenyl)diazenyl) phenyl)amino]-4-oxobutyl)-4-((tert-butoxycarbonyl)amino) pentanedioate
2.9  \((2S,4S)-2-(4-((4-(E)-(4-(2-aminoethyl)amino)phenyl)diazlenyl)phenyl)amino)-4-oxobutyl)-4-((tert-butoxycarbonyl)amino)pentanedioic acid, (10)\)
2.10 (2S,4S)-2-Amino-4-(4-oxo-4-((4-((38-oxo-2,5,8,11,14,17,20,23,26,29,32,35-dodecaoxa-39-azahentetracontan-41-yl)amino)phenyl)diazenyl)phenyl)-amino)butyl)pentanedioic acid, D-AG\textsubscript{12,445}
3 Supporting Figures

Figure S1: HPLC traces of the BGAG library demonstrating its purity.
Figure S2: Expression and fluorophore labeling with benzylguanine-Alexa-647 (BG-Alexa-647) of SNAP-mGluR2-GFP in HEK293T cells. First column: GFP fluorescence. Second column: BG-Alexa-647 fluorescence. Third column: merge. Scale bars represents 50 μM (top) and 10 μM (bottom).
Figure S3: SDS-PAGE after *in vitro* SNAP-tag labeling (New England Biolabs, #P9312S) with BGAG$_{12}$ and d-MAG. Reductive (dithiothreitol, DTT), oxidative (oxidized glutathione, GSSG) or neutral conditions (no additive) were employed according to the manufacturer’s instructions. BGAG$_{12}$ reacts with the SNAP-tag under each condition, while d-MAG reacts only under oxidative and neutral conditions (although slower as indicated by the unlabelled SNAP-tag band) and is unreactive towards the SNAP-tag under reductive conditions.
Figure S4: Further characterization of SNAG-mGluR2. a) Representative patch-clamp recording demonstrates reversible, bistable optical control of SNAP-mGluR2 with BGAG12 (i.e. SNAG-mGluR2). SNAG-mGluR2 is activated by a brief pulse of UV light (λ = 380 nm, gray) and deactivated with a brief pulse of green light (λ = 500 nm, green). Black bar represents no light. b) When wild type mGluR2 (mGluR2wt) is incubated with BGAG12, no photoresponse is seen after wash-out but application of 1 mM glutamate still produces a large inward current. c) Photoactivation of SNAG-mGluR2 is fully blocked by the competitive mGluR2 antagonist LY341495. d) Glutamate concentration-response curves for mGluR2wt and SNAP-mGluR2 with or without BGAG12 labeling. Glutamate titration was performed in the dark for all conditions.
Figure S5: Summary of labeling conditions for BGAG<sub>12</sub> on SNAP-mGluR2 in HEK293T cells. a-d) Representative traces showing photoactivation of SNAG-mGluR2 following incubation with BGAG<sub>12</sub> for 45 minutes in standard extracellular solution at various concentrations. Purple bars indicate 380 nm light and green bars indicate 500 nm light. e-f) Representative trace showing photoactivation of SNAG-mGluR2 following overnight labeling with 100 nM (e) or 10 nM (f) BGAG<sub>12</sub>. 
Figure S6: Optical control of SNAG-mGluR2 with AGs in HEK 293T cells. 

a) Summary of photoswitch efficiency relative to 1 mM glutamate for AG12 and AG12,460 either treated as BGAG12 (incubated for 1 h (10µM) then washed) or with the photoswitch present (washed in (100 µM)). Error bars represent SEM; the numbers of cells tested are in parentheses. 

b) Representative patch-clamp recording demonstrates the reversible optical control of SNAG-mGluR2 with AG12. SNAG-mGluR2 is activated with a UV light (λ = 380 nm, violet) and deactivated with blue light (λ = 440 nm, blue). Application of saturating 1 mM glutamate gives full activation and prevents further photoactivation in all cases.
Figure S7: Optical control of SNAG-mGluR2 with variable length BGAGs in HEK 293T cells. a-c) Representative patch-clamp recording demonstrates the reversible optical control of SNAG-mGluR2 with either BGAG_0 (a), BGAG_4 (b), or BGAG_8 (c). SNAG-mGluR2 is activated with a brief pulse of UV light (λ = 390 nm, gray) and deactivated with a brief pulse of green light (λ = 500 nm, green). Application of saturating 1 mM glutamate gives full activation and prevents further photoactivation in all cases. d) Summary of photoswitch efficiency relative to 1 mM glutamate for all BGAG variants. Error bars represent SEM; the numbers of cells tested are in parentheses.
Figure S8: BG-Alexa-647 labeling controls for hippocampal neurons. **a-b)** Representative images showing BG-Alexa-647 labeling of GFP-expressing neurons in the absence (**a**)) or presence (**b**) of SNAP-mGluR2 coexpression.
**Figure S9:** SNAG-mGluR2 mediated optical modulation of short term plasticity. Summary of response to high frequency (20 Hz) stimulation of a SNAG-mGluR2-expressing neuron in the presence of 380 nm (violet) or 500 nm (green) illumination. EPSC amplitude is normalized to the amplitude of the first pulse within the train.
4 References

1. Keppler, A. et al. A general method for the covalent labeling of fusion proteins with small molecules in vivo. *Nat. Biotechnol.* **21**, 86–89 (2003).

2. Levitz, J. et al. Optical control of metabotropic glutamate receptors. *Nat. Neurosci.* **16**, 507–16 (2013).

3. Di Antonio, M. et al. Selective RNA versus DNA G-quadruplex targeting by situ click chemistry. *Angew. Chemie - Int. Ed.* **51**, 11073–11078 (2012).

4. Chen, J. J. & Aduda, V. DMSO-Aided o-Iodoxybenzoic Acid (IBX) Oxidation of Fmoc-Protected Amino Alcohols. *Synth. Commun.* **37**, 3493–3499 (2007).